Synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-04. Anything still debated is marked as such rather than presented as settled.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
| Property | Value | Notes |
|---|---|---|
| Main study model | Rodents, rats and mice | Underpins most of the published data |
| Common routes in studies | Subcutaneous, intraperitoneal, oral | Varies with the experimental design |
| Common analytical method | Reversed-phase HPLC, LC-MS | Used for identity and purity checks |
| Human evidence base | Small | Few trials reported, with limited findings |
| Regulatory status | Varies by jurisdiction | Not an approved medicine in most places |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
=== 2003 === 15 March Space Shuttle: Human Time Bomb? about STS-107, which broke up on 1 February 2003; Bill Readdy of NASA; technology writer Dwayne A. Day; the shuttle engines burned 1.5 tonnes per second; physicist Ted Postol of MIT; Vladimir Titov and Gennady Strekalov deployed a launch escape system on Soyuz 7K-ST No.16L on 26 September 1983; the shuttle design was hampered by a need for a large-enough payload bay, to take 60-ft spy satellites for the USAF, and the shuttle's original companion launch vehicle (similar to the North American DC-3) was exchanged for a disposable fuel tank; in May 1995 for STS-70, woodpeckers destroyed a large part of the foam coating on the fuel tank next to Discovery on the launch pad - NASA bought six lifesize owls from a nearby supermarket to frighten the woodpeckers away; on 7 October 2002 on the launch of STS-112, foam broke away from the fuel tank, causing damage, which NASA ignored; Jeff Hoffmann; on 1 February 2003 at around 8am Nacogdoches, Texas was hit by debris. Narrated by Heather Couper, produced by Stuart Carter, directed by Alex Hearle, made by Pioneer Productions. Filmed, edited and broadcast only twenty three days after being commissioned Self-Experimenters, about self-experimentation in medicine; neuroscientist Simon Gandevia from the Prince of Wales Medical Research Institute (since 2010, Neuroscience Research Australia); Canadian thermophysiologist Gordon Giesbrecht at the University of Manitoba in Winnipeg; medicinal chemist and psychopharmacologist Sasha Shulgin; medicinal chemist David E.
==== NMR spectroscopy ==== The proton resonances of alkanes are usually found at δH = 0.5–1.5. The carbon-13 resonances depend on the number of hydrogen atoms attached to the carbon: δC = 8–30 (primary, methyl, –CH3), 15–55 (secondary, methylene, –CH2–), 20–60 (tertiary, methyne, C–H) and quaternary. The carbon-13 resonance of quaternary carbon atoms is characteristically weak, due to the lack of nuclear Overhauser effect and the long relaxation time, and can be missed in weak samples, or samples that have not been run for a sufficiently long time.
Roller chain or bush roller chain is the type of chain drive most commonly used for transmission of mechanical power on many kinds of domestic, industrial and agricultural machinery, including conveyors, wire- and tube-drawing machines, printing presses, cars, motorcycles, and bicycles. It consists of a series of short cylindrical rollers held together by side links. It is driven by a toothed wheel called a sprocket. It is a simple, reliable, and efficient means of power transmission. Sketches by Leonardo da Vinci in the 16th century show a chain with a roller bearing. In 1800, James Fussell patented a roller chain on development of his balance lock and in 1880 Hans Renold patented a bush roller chain.
=== Hank Rizzoli === Hank Rizzoli (Ray Romano) is a photographer who is hired by the Braverman family for a family picture in season four. Sarah ultimately becomes Hank's assistant. While at first he disliked Sarah, the two begin a relationship that has problems as Sarah still has feelings for Mark Cyr. In season five, Hank begins a mentor-mentee relationship with Max and teaches him about photography. After spending time with Max, and reading a book about Asperger syndrome that Adam lent him (after one of Max's outbursts), Hank begins to realize that he shares many social qualities with Max and that he may have Asperger syndrome himself. Hank has a daughter, Ruby, from his previous marriage. When Amber is upset because Ryan York, her ex-fiancé, is involved in an accident, Hank offers to drive Amber the long distance to see Ryan. In season six, after Sarah and Hank move in together, Hank begins to bond with Amber and Drew. He helps Amber assemble her crib and asks Drew to be his best man. Hank and Sarah marry in the series finale.
Sources: en.wikipedia.org
== Other uses == Gar (music), a Tibetan form of chanting Gar (spear), an Old English word meaning "spear" Tambor-class submarine, a US Navy class whose later members were sometimes attributed to the "Gar class" USS Gar (SS-206), a World War II submarine Gardiner railway station, Melbourne Garfield "Gar" Logan, DC Comics superhero Beast Boy Galeya language of Papua New Guinea, ISO 639-3 code Gliese 486, a star with the proper name Gar
=== Mortality risk === A 2012 study found a significantly lower ischemic heart disease mortality (-29%) and overall cancer incidence (-18%) in vegetarians in comparison to nonvegetarians. A 2017 review found a lower mortality (−25%) from ischemic heart disease.
Vitamin B12 is absorbed by a B12-specific transport proteins or via passive diffusion. Transport-mediated absorption and tissue delivery is a complex process involving three transport proteins: haptocorrin (HC), intrinsic factor (IF) and transcobalamin II (TC2), and respective membrane receptor proteins (Figure). HC is present in saliva. As vitamin-containing food is digested by hydrochloric acid and pepsin secreted into the stomach, HC binds the vitamin and protects it from acidic degradation. Upon leaving the stomach the hydrochloric acid of the chyme is neutralized in the duodenum by bicarbonate, and pancreatic proteases release the vitamin from HC, making it available to be bound by IF, which is a protein secreted by gastric parietal cells in response to the presence of food in the stomach. IF delivers the vitamin to receptor proteins cubilin and amnionless, which together form the cubam receptor in the distal ileum. The receptor is specific to the IF-B12 complex, and so will not bind to any vitamin content that is not bound to IF. Investigations into the intestinal absorption of B12 confirm that the upper limit of absorption per single oral dose is about 1.5 μg, with 50% efficiency. In contrast, the passive diffusion process of B12 absorption — normally a small portion of total absorption of the vitamin from food consumption — may exceed the haptocorrin- and IF-mediated absorption when oral doses of B12 are large, with roughly 1% efficiency.
The two main types of dialysis, hemodialysis and peritoneal dialysis, remove wastes and excess water from the blood in different ways. Hemodialysis removes wastes and water by circulating blood outside the body through an external filter, called a dialyzer, that contains a semipermeable membrane. The blood flows in one direction and the dialysate flows in the opposite. The counter-current flow of the blood and dialysate maximizes the concentration gradient of solutes between the blood and dialysate, which helps to remove more urea and creatinine from the blood. The concentrations of solutes normally found in the urine (for example potassium, phosphorus and urea) are undesirably high in the blood, but low or absent in the dialysis solution, and constant replacement of the dialysate ensures that the concentration of undesired solutes is kept low on this side of the membrane. The dialysis solution has levels of minerals like potassium and calcium that are similar to their natural concentration in healthy blood. For another solute, bicarbonate, dialysis solution level is set at a slightly higher level than in normal blood, to encourage the diffusion of bicarbonate into the blood, to act as a pH buffer to neutralize the metabolic acidosis that is often present in these patients. The levels of the components of dialysate are typically prescribed by a nephrologist according to the needs of the individual patient. In peritoneal dialysis, wastes and water are removed from the blood inside the body using the peritoneum as a natural semipermeable membrane.
UIP pattern: Honeycombing, with or without peripheral traction bronchiectasis; or bronchiolectasis (dilatation of the terminal bronchioles) Predominantly subpleural and basal Often heterogenous distribution, being occasionally diffuse, and may be asymmetrical There may be superimposed CT features such as mild ground-glass opacity, reticular pattern and pulmonary ossification.
Sources: en.wikipedia.org
=== Medical insurance coverage === Insurance companies in the United States typically require the physician to provide evidence that a woman's large breasts cause headaches or back and neck pain before they will pay for breast reduction. Insurance companies also mandate a woman who is overweight, which is often the case with gigantomastia, to first lose a certain amount of weight. They also commonly require the patient to try alternative treatments like physical therapy for a year or more.
While advertising of tobacco products is banned in most countries, television and radio e-cigarette advertising in several countries may be indirectly encouraging traditional cigarette use. E-cigarette advertisements are also in magazines, newspapers, online, and in retail stores. Between 2010 and 2014, e-cigarettes were second only to cigarettes as the top advertised product in magazines. As cigarette companies have acquired the largest e-cigarette brands, they currently benefit from a dual market of smokers and e-cigarette users while simultaneously presenting themselves as agents of harm reduction. This raises concerns about the appropriateness of endorsing a product that directly profits the tobacco industry. There is no evidence that the cigarette brands are selling e-cigarettes as part of a plan to phase out traditional cigarettes, despite some stating to want to cooperate in "harm reduction". E-cigarette advertising for using e-cigarettes as a quitting tool have been seen in the US, UK, and China, which have not been supported by regulatory bodies. In the US, six large e-cigarette businesses spent $59.3 million on promoting e-cigarettes in 2013. In the US and Canada, over $2 million is spent yearly on promoting e-cigarettes online. E-cigarette websites often made unscientific health statements in 2012. The ease to get past the age verification system at e-cigarette company websites allows underage individuals to access and be exposed to marketing.
By the mid-1980s, the term in situ was adopted in materials science, particularly in the field of heterogeneous catalysis, where a catalyst in one phase facilitates a chemical reaction in a different phase. The term later expanded beyond catalysis and is now applied across various disciplines of materials science, alongside the opposite designation ex situ. For example, in situ describes the study of a sample maintained in a steady state condition within a controlled environment, where specific parameters such as temperature or pressure are regulated. This approach allows researchers to observe materials under conditions that replicate their functional states. Examples include a sample held at a fixed temperature inside a cryostat, an electrode material operating within an electric battery, or a specimen enclosed within a sealed container to protect it from external influences. In transmission electron microscopy (TEM) and scanning transmission electron microscopy (STEM), in situ refers to the observation of materials as they are exposed to external stimuli within the microscope, under conditions that mimic their natural environments. This enables real-time observation of material behavior at the nanoscale. External stimuli in in situ TEM/STEM experiments may include mechanical loading, pressure, temperature variation, electrical biasing, radiation, and environmental exposure to gases, liquids, or magnetic fields, individually or in combination.
=== Refresh frequency limits for HDR video === Color depth of 10 bpc (30 bit/px or 1.07 billion colors) is assumed for all formats in these tables. This color depth is a requirement for various common HDR standards, such as HDR10. It requires 25% more bandwidth than standard 8 bpc video. HDR extensions were defined in version 1.4 of the DisplayPort standard. Some displays support these HDR extensions, but may only implement HBR2 transmission mode if the extra bandwidth of HBR3 is unnecessary (for example, on 4K 60 Hz HDR displays). Since there is no definition of what constitutes a "DisplayPort 1.4" device, some manufacturers may choose to label these as "DP 1.2" devices despite their support for DP 1.4 HDR extensions. As a result, DisplayPort "version numbers" should not be used as an indicator of HDR support.
On the other hand, the findings of animal studies of methenamine and carcinogenicity have also been questioned by some authors, though this topic is controversial. Antibiotics are known to disrupt the gut, urinary tract, and vaginal microbiota. This has been associated with increased risk of recurrent UTIs. Methenamine has been limitedly studied in this regard, but was found in one small study to preserve urinary microbial diversity. However, more studies are needed to assess the influence of methenamine on the host microbiome, both in the urinary tract and elsewhere in the body. Side effects of the topical form of methenamine for hyperhidrosis include dry skin, among others.
Sources: en.wikipedia.org
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.
They are best described as working hypotheses. Supporting data come mainly from cell cultures and animal tissue, using markers such as growth factors and inflammatory signals. Confirmatory human studies have not been reported.
Status depends on the country. In some places it is treated as a research chemical available without a prescription, while elsewhere it falls under prescription or controlled rules. It holds no general marketing approval as a therapeutic product.
It is a synthetic peptide. Its design was inspired by a fragment of a protein found in human gastric juice, but the fifteen-amino-acid molecule itself is made in a laboratory and is not a normal component of food or of human tissue in appreciable amounts.